Document

0000200406-19-000049.txt : 20190716 0000200406-19-000049.hdr.sgml : 20190716 20190716080032 ACCESSION NUMBER: 0000200406-19-000049 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20190716 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190716 DATE AS OF CHANGE: 20190716 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 19956221 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 8-K 1 a20192qcover.htm 8-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

July 16, 2019

(Exact name of registrant as specified in its charter)



New Jersey	I-3215	22-1024240
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $1.00	JNJ	New York Stock Exchange
4.75% Notes Due November 2019	JNJ	New York Stock Exchange
0.250% Notes Due January 2022	JNJ	New York Stock Exchange
0.650% Notes Due May 2024	JNJ	New York Stock Exchange
5.50% Notes Due November 2024	JNJ	New York Stock Exchange
1.150% Notes Due November 2028	JNJ	New York Stock Exchange
1.650% Notes Due May 2035	JNJ	New York Stock Exchange

Item 2.02 Results of Operations and Financial Condition

On July 16, 2019, Johnson & Johnson issued the attached press release announcing its sales and earnings for the second quarter ended June 30, 2019.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.



Exhibit No.	Description of Exhibit
99.15	Press Release dated July 16, 2019 for the period ended June 30, 2019.
99.2O	Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the second quarter.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



		Johnson & Johnson
			(Registrant)
Date:	July 16, 2019	By:	/s/ Ronald A. Kapusta
			Ronald A. Kapusta Controller (Principal Accounting Officer)

EX-99.15 2 a2019q2exhibit9915.htm EXHIBIT 99.15 Exhibit

Exhibit 99.15

JOHNSON & JOHNSON REPORTS 2019 SECOND-QUARTER RESULTS:


•	Sales of $20.6 billion reflecting a decline of 1.3%, operational growth of 1.6%* and adjusted operational growth of 3.7%*


•	EPS of $2.08 increased 43.4%; adjusted EPS of $2.58 increased 22.9%*; includes gain from sale of Advanced Sterilization Products (ASP) business


•	Operational sales guidance increased due to strength of business; EPS guidance range maintained

New Brunswick, N.J. (July 16, 2019) - Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2019. “We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “Our pipelines continue to progress with the launch of new products and several regulatory submissions and approvals, which positions us well to deliver the next wave of transformational products and solutions. I am proud of our talented colleagues across Johnson & Johnson who continue to deliver significant healthcare advances to improve the lives of patients and consumers around the world.”

OVERALL FINANCIAL RESULTS:

¹Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

⁴ Excludes intangible amortization expense and special items

REGIONAL SALES RESULTS:

¹ Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

SEGMENT SALES RESULTS:

¹ Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

SEGMENT COMMENTARY:

Consumer

Consumer worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 2.3%* driven by NEUTROGENA, AVEENO and OGX beauty products, over-the-counter products including ZYRTEC upper respiratory and MOTRIN analgesic products, international LISTERINE mouthwash in Oral Care products and U.S. Baby Care products.

Pharmaceutical

Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures grew 4.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, OPSUMIT (macitentan), an oral endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease progression, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with non-metastatic castration-resistant prostate cancer and PREZISTA/PREZCOBIX/REZOLSTA/ SYMTUZA (D/C/F/TAF) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, partially offset by declines in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, and U.S. ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer due to biosimilar and generic entrants.

Medical Devices

Worldwide Medical Devices operational sales, excluding the net impact of acquisitions and divestitures grew 3.2%* driven by the growth of electrophysiology products in the Interventional Solutions business, endocutters and international energy products in the Advanced Surgery business. As previously disclosed, the divestiture of the ASP business was completed, resulting in an approximate $2.0 billion pretax gain in the quarter.

NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:

The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the company’s website at news releases.

Pipeline Updates



Regulatory Approvals	IMBRUVICA (ibrutinib) - CHMP Positive Opinions in combination with obinutuzumab in CLL and in combination with rituximab in WM	(press release)
Regulatory Approvals	DARZALEX (daratumumab) - Newly diagnosed patients with Multiple Myeloma in combination with Lenalidomide and Dexamethasone (U.S.)	(press release)
Regulatory Submissions	DARZALEX (daratumumab) - Subcutaneous formulation in multiple myeloma (U.S.)¹	(press release)
	ERLEADA (apalutamide) - Metastatic Hormone-Sensitive Prostate Cancer (EU)	(press release)
	ERLEADA (apalutamide) - Metastatic Castration - Sensitive Prostate Cancer (U.S)	(press release)
	Rilpivirine and Cabotegravir - Monthly, Injectable, Two-Drug Regimen for Treatment of HIV	(press release)

¹ Subsequent to the quarter

FULL YEAR 2019 GUIDANCE:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.



	July 2019	April 2019

($ in Billions, except EPS)



Adjusted Operational Sales^1,2 Change vs. Prior Year	3.2% - 3.7%	2.5% - 3.5%
Operational Sales² Change vs. Prior Year	$82.4 to $83.2 1.0% - 2.0%	$82.0 to $82.8 0.5% - 1.5%
Estimated Reported Sales³ Change vs. Prior Year	$80.8 to $81.6 (1.0%) - 0.0%	$80.4 to $81.2 (1.5%) - (0.5%)

Adjusted Operational EPS (Diluted)^2,4 Change vs. Prior Year	$8.73 to $8.83 6.7% - 7.9%	$8.73 to $8.83 6.7% - 7.9%
Adjusted EPS (Diluted)^3,4 Change vs. Prior Year	$8.53 to $8.63 4.3% - 5.5%	$8.53 to $8.63 4.3% - 5.5%

¹ Non-GAAP financial measure;excludes the net impact of acquisitions and divestitures

² Non-GAAP financial measure; excludes the impact of translational currency

³ Calculated using Euro Average Rate: July 2019 = $1.12; Euro Average Rate: April 2019 = $1.12 (Illustrative purposes only)

⁴Non-GAAP financial measure; excludes intangible amortization expense and special items

Other modeling considerations will be provided on the webcast.

WEBCAST INFORMATION:

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at events-and-presentations.

ABOUT JOHNSON & JOHNSON:

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

NON-GAAP FINANCIAL MEASURES:

*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at quarterly-results.

Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investors section of the company's website at quarterly-results.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Press Contacts: Investor Contacts:

Ernie Knewitz Christopher DelOrefice

(732) 524-6623 (732) 524-2955

(917) 697-2318 (M)

Cristal Downing Lesley Fishman

(732) 524-3283 (732) 524-3922

(908) 616-8833 (M)

EX-99.2O 3 a2019q2exhibit992o.htm EXHIBIT 99.2O Exhibit

Exhibit 99.2O



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER
			Percent Change
	2019	2018	Total		Operations	Currency
Sales to customers by
geographic area

U.S.	$ 10,403	10,640	(2.2)	%	(2.2)	—

Europe	4,733	4,810	(1.6)		4.7	(6.3)
Western Hemisphere excluding U.S.	1,455	1,540	(5.5)		4.2	(9.7)
Asia-Pacific, Africa	3,971	3,840	3.4		7.2	(3.8)
International	10,159	10,190	(0.3)		5.5	(5.8)

Worldwide	$ 20,562	20,830	(1.3)	%	1.6	(2.9)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SIX MONTHS
			Percent Change
	2019	2018	Total		Operations	Currency
Sales to customers by
geographic area

U.S.	$ 20,532	20,591	(0.3)	%	(0.3)	—

Europe	9,342	9,607	(2.8)		4.6	(7.4)
Western Hemisphere excluding U.S.	2,958	3,107	(4.8)		6.5	(11.3)
Asia-Pacific, Africa	7,751	7,534	2.9		7.0	(4.1)
International	20,051	20,248	(1.0)		5.8	(6.8)

Worldwide	$ 40,583	40,839	(0.6)	%	2.7	(3.3)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER
			Percent Change
	2019	2018	Total		Operations	Currency
Sales to customers by
segment of business

Consumer
U.S.	$ 1,537	1,476	4.1	%	4.1	—
International	2,007	2,028	(1.0)		4.9	(5.9)
	3,544	3,504	1.2		4.6	(3.4)

Pharmaceutical
U.S.	5,783	5,899	(2.0)		(2.0)	—
International	4,746	4,455	6.5		12.9	(6.4)
	10,529	10,354	1.7		4.4	(2.7)

Medical Devices
U.S.	3,083	3,265	(5.6)		(5.6)	—
International	3,406	3,707	(8.1)		(2.9)	(5.2)
	6,489	6,972	(6.9)		(4.1)	(2.8)

U.S.	10,403	10,640	(2.2)		(2.2)	—
International	10,159	10,190	(0.3)		5.5	(5.8)
Worldwide	$ 20,562	20,830	(1.3)	%	1.6	(2.9)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SIX MONTHS
			Percent Change
	2019	2018	Total		Operations	Currency
Sales to customers by
segment of business

Consumer
U.S.	$ 2,975	2,912	2.2	%	2.2	—
International	3,887	3,990	(2.6)		4.3	(6.9)
	6,862	6,902	(0.6)		3.4	(4.0)

Pharmaceutical
U.S.	11,365	11,253	1.0		1.0	—
International	9,408	8,945	5.2		12.5	(7.3)
	20,773	20,198	2.8		6.1	(3.3)

Medical Devices
U.S.	6,192	6,426	(3.6)		(3.6)	—
International	6,756	7,313	(7.6)		(1.6)	(6.0)
	12,948	13,739	(5.7)		(2.6)	(3.1)

U.S.	20,532	20,591	(0.3)		(0.3)	—
International	20,051	20,248	(1.0)		5.8	(6.8)
Worldwide	$ 40,583	40,839	(0.6)	%	2.7	(3.3)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SECOND QUARTER

	2019			2018			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$ 20,562		100.0	$ 20,830		100.0	(1.3)
Cost of products sold	6,940		33.8	6,927		33.3	0.2
Gross Profit	13,622		66.2	13,903		66.7	(2.0)
Selling, marketing and administrative expenses	5,546		27.0	5,743		27.5	(3.4)
Research and development expense	2,666		13.0	2,639		12.7	1.0
Interest (income) expense, net	(5)		0.0	127		0.6
Other (income) expense, net	(1,683)		(8.2)	364		1.7
Restructuring	57		0.2	57		0.3
Earnings before provision for taxes on income	7,041		34.2	4,973		23.9	41.6
Provision for taxes on income	1,434		6.9	1,019		4.9	40.7
Net earnings	$ 5,607		27.3	$ 3,954		19.0	41.8

Net earnings per share (Diluted)	$ 2.08			$ 1.45			43.4

Average shares outstanding (Diluted)	2,691.7			2,721.3

Effective tax rate	20.4	%		20.5	%

Adjusted earnings before provision for taxes and net earnings ^{(1) (A)}
Earnings before provision for taxes on income	$ 8,614		41.9	$ 7,014		33.7	22.8
Net earnings	$ 6,950		33.8	$ 5,718		27.5	21.5
Net earnings per share (Diluted)	$ 2.58			$ 2.10			22.9
Effective tax rate	19.3	%		18.5	%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SIX MONTHS

	2019			2018			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$ 40,583		100.0	$ 40,839		100.0	(0.6)
Cost of products sold	13,555		33.4	13,541		33.2	0.1
Gross Profit	27,028		66.6	27,298		66.8	(1.0)
Selling, marketing and administrative expenses	10,765		26.5	11,006		27.0	(2.2)
Research and development expense	5,524		13.6	5,043		12.3	9.5
In-process research and development	890		2.2	—		—
Interest (income) expense, net	(2)		0.0	272		0.7
Other (income) expense, net	(1,705)		(4.2)	424		1.0
Restructuring	93		0.3	99		0.2
Earnings before provision for taxes on income	11,463		28.2	10,454		25.6	9.7
Provision for taxes on income	2,107		5.1	2,133		5.2	(1.2)
Net earnings	$ 9,356		23.1	$ 8,321		20.4	12.4

Net earnings per share (Diluted)	$ 3.47			$ 3.05			13.8

Average shares outstanding (Diluted)	2,697.0			2,728.5

Effective tax rate	18.4	%		20.4	%

Adjusted earnings before provision for taxes and net earnings ^{(1) (A)}
Earnings before provision for taxes on income	$ 15,481		38.1	$ 13,872		34.0	11.6
Net earnings	$ 12,611		31.1	$ 11,353		27.8	11.1
Net earnings per share (Diluted)	$ 4.68			$ 4.16			12.5
Effective tax rate	18.5	%		18.2	%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
	Second Quarter		% Incr. /
(Dollars in Millions Except Per Share Data)	2019	2018	(Decr.)

Earnings before provision for taxes on income - as reported	$ 7,041	4,973	41.6	%
Intangible asset amortization expense	1,118	1,084
In-process research and development	—	—
Litigation expense, net	409	703
Restructuring/Other⁽¹⁾	142	176
Actelion acquisition related cost	51	64
AMO acquisition related cost	13	25
Auris Health acquisition related	(9)	—
Unrealized loss/(gain) on securities	(148)	(39)
Diabetes asset impairment	—	4
Other	(3)	24
Earnings before provision for taxes on income - as adjusted	$ 8,614	7,014	22.8	%

Net Earnings - as reported	$ 5,607	3,954	41.8	%
Intangible asset amortization expense	979	967
In-process research and development	—	—
Litigation expense, net	342	609
Restructuring/Other	116	152
Actelion acquisition related cost	47	64
AMO acquisition related cost	10	22
Auris Health acquisition related	(7)	—
Unrealized loss/(gain) on securities	(117)	(31)
Diabetes asset impairment	—	3
Impact of tax legislation⁽²⁾	—	(40)
Other	(27)	18
Net Earnings - as adjusted	$ 6,950	5,718	21.5	%

Diluted Net Earnings per share - as reported	$ 2.08	1.45	43.4	%
Intangible asset amortization expense	0.36	0.36
In-process research and development	—	—
Litigation expense, net	0.13	0.22
Restructuring/Other	0.04	0.06
Actelion acquisition related cost	0.02	0.02
AMO acquisition related cost	—	0.01
Auris Health acquisition related	—	—
Unrealized loss/(gain) on securities	(0.04)	(0.01)
Diabetes asset impairment	—	—
Impact of tax legislation	—	(0.02)
Other	(0.01)	0.01
Diluted Net Earnings per share - as adjusted	$ 2.58	2.10	22.9	%

Operational Diluted Net Earnings per share - as adjusted
at 2017 foreign currency exchange rates		2.04

Impact of currency at 2018 foreign currency exchange rates	0.05	0.06

Operational Diluted Net Earnings per share - as adjusted
at 2018 foreign currency exchange rates	$ 2.63	2.10	25.2	%

⁽¹⁾ Includes $38M recorded in cost of products sold and $47M recorded in other (income) expense for the second quarter 2019. Includes $44M recorded in cost of products sold and $75M recorded in other (income) expense for the second quarter 2018.

⁽²⁾ Includes foreign currency translation



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
	Six Months YTD			% Incr. /
(Dollars in Millions Except Per Share Data)	2019		2018	(Decr.)

Earnings before provision for taxes on income - as reported	$ 11,463		10,454	9.7	%
Intangible asset amortization expense	2,248		2,199
In-process research and development	890		—
Litigation expense, net	832		703
Restructuring/Other⁽¹⁾	232		283
Actelion acquisition related cost	90		160
AMO acquisition related cost	41		46
Auris Health acquisition related	(9	)	—
Unrealized loss/(gain) on securities	(306	)	(12)
Diabetes asset impairment	—		4
Other	—		35
Earnings before provision for taxes on income - as adjusted	$ 15,481		13,872	11.6	%

Net Earnings - as reported	$ 9,356		8,321	12.4	%
Intangible asset amortization expense	1,825		1,963
In-process research and development	703		—
Litigation expense, net	684		609
Restructuring/Other	191		233
Actelion acquisition related cost	84		156
AMO acquisition related cost	33		39
Auris Health acquisition related	(7	)	—
Unrealized loss/(gain) on securities	(242	)	(10)
Diabetes asset impairment	—		3
Impact of tax legislation⁽²⁾	—		12
Other	(16	)	27
Net Earnings - as adjusted	$ 12,611		11,353	11.1	%

Diluted Net Earnings per share - as reported	$ 3.47		3.05	13.8	%
Intangible asset amortization expense	0.68		0.72
In-process research and development	0.26		—
Litigation expense, net	0.26		0.22
Restructuring/Other	0.07		0.09
Actelion acquisition related cost	0.03		0.05
AMO acquisition related cost	0.01		0.01
Auris Health acquisition related	—		—
Unrealized loss/(gain) on securities	(0.09	)	—
Diabetes asset impairment	—		—
Impact of tax legislation	—		0.01
Other	(0.01	)	0.01
Diluted Net Earnings per share - as adjusted	$ 4.68		4.16	12.5	%

Operational Diluted Net Earnings per share - as adjusted
at 2017 foreign currency exchange rates			3.97

Impact of currency at 2018 foreign currency exchange rates	0.13		0.19

Operational Diluted Net Earnings per share - as adjusted
at 2018 foreign currency exchange rates	$ 4.81		4.16	15.6	%

⁽¹⁾ Includes $61M recorded in cost of products sold and $78M recorded in other (income) expense for six months 2019 YTD. Includes $50M recorded in cost of products sold and $134M recorded in other (income) expense for six months 2018 YTD.

⁽²⁾ Includes foreign currency translation



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth ^(A)
SECOND QUARTER 2019 ACTUAL vs. 2018 ACTUAL

Segments

	Consumer	Pharmaceutical	Medical Devices	Total
WW As Reported	1.2%	1.7%	(6.9)%	(1.3)%
U.S.	4.1%	(2.0)%	(5.6)%	(2.2)%
International	(1.0)%	6.5%	(8.1)%	(0.3)%

WW Currency	(3.4)	(2.7)	(2.8)	(2.9)
U.S.	—	—	—	—
International	(5.9)	(6.4)	(5.2)	(5.8)

WW Operational	4.6%	4.4%	(4.1)%	1.6%
U.S.	4.1%	(2.0)%	(5.6)%	(2.2)%
International	4.9%	12.9%	(2.9)%	5.5%

Beauty
Nizoral	0.6			0.1
U.S.	0.3			0.0
International	0.7			0.1

OTC
Zarbees	(0.6)			(0.1)
U.S.	(1.4)			(0.2)
International	0.0			0.0

Diabetes Care
LifeScan			5.1	1.7
U.S.			4.0	1.2
International			6.2	2.3

Beauty
RoC	0.7			0.1
U.S.	1.3			0.2
International	0.3			0.1

Beauty
Dr. Ci Labo - Japan	(3.0)			(0.5)
U.S.	0.0			0.0
International	(5.2)			(1.0)

Specialty Surgery
Advanced Sterilization Products			2.0	0.7
U.S.			3.0	0.9
International			1.2	0.5

All Other Acquisitions and Divestitures	0.0	0.0	0.1	0.0
U.S.	0.0	0.0	0.1	0.0
International	0.1	0.0	0.1	0.0

WW Adjusted Operational	2.3%	4.4%	3.2%	3.7%
U.S.	4.4%	(2.0)%	1.6%	0.0%
International	0.7%	12.9%	4.7%	7.6%

Note: Percentages are based on actual, non-rounded figures and may not sum

^(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth ^(A)
SIX MONTHS 2019 ACTUAL vs. 2018 ACTUAL

Segments

	Consumer	Pharmaceutical	Medical Devices	Total
WW As Reported	(0.6)%	2.8%	(5.7)%	(0.6)%
U.S.	2.2%	1.0%	(3.6)%	(0.3)%
International	(2.6)%	5.2%	(7.6)%	(1.0)%

WW Currency	(4.0)	(3.3)	(3.1)	(3.3)
U.S.	—	—	—	—
International	(6.9)	(7.3)	(6.0)	(6.8)

WW Operational	3.4%	6.1%	(2.6)%	2.7%
U.S.	2.2%	1.0%	(3.6)%	(0.3)%
International	4.3%	12.5%	(1.6)%	5.8%

Beauty
Nizoral	0.5			0.1
U.S.	0.3			0.0
International	0.6			0.1

OTC
Zarbees	(0.7)			(0.1)
U.S.	(1.7)			(0.2)
International	0.0			0.0

Diabetes Care
LifeScan			5.1	1.7
U.S.			3.9	1.2
International			6.1	2.3

Beauty
RoC	0.8			0.1
U.S.	1.4			0.2
International	0.3			0.1

Beauty
Dr. Ci Labo - Japan	(2.6)			(0.4)
U.S.	0.0			0.0
International	(4.4)			(0.9)

Specialty Surgery
Advanced Sterilization Products			1.1	0.4
U.S.			1.5	0.5
International			0.6	0.2

All Other Acquisitions and Divestitures	0.1	0.0	0.1	0.1
U.S.	0.0	0.0	0.2	0.1
International	0.2	0.0	0.1	0.1

WW Adjusted Operational	1.5%	6.1%	3.8%	4.6%
U.S.	2.2%	1.0%	2.1%	1.5%
International	1.0%	12.5%	5.3%	7.7%

Note: Percentages are based on actual, non-rounded figures and may not sum

^(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2019	2018	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT⁽²⁾

BABY CARE
US	$	99	89	11.5	%	11.5	%	—	%
Intl		344	367	(6.3	)	0.0		(6.3	)
WW		443	456	(2.8	)	2.2		(5.0	)

BEAUTY
US		663	637	4.1		4.1		—
Intl		539	472	14.1		19.5		(5.4	)
WW		1,202	1,109	8.4		10.7		(2.3	)

ORAL CARE
US		155	157	(1.6	)	(1.6	)	—
Intl		234	236	(0.7	)	5.3		(6.0	)
WW		389	393	(1.1	)	2.5		(3.6	)

OTC
US		484	454	6.6		6.6		—
Intl		580	612	(5.1	)	0.0		(5.1	)
WW		1,064	1,066	(0.1	)	2.8		(2.9	)

WOMEN'S HEALTH
US		3	4	(10.3	)	(10.3	)	—
Intl		250	276	(9.5	)	(1.3	)	(8.2	)
WW		253	280	(9.5	)	(1.4	)	(8.1	)

WOUND CARE / OTHER
US		132	135	(1.9	)	(1.9	)	—
Intl		61	65	(6.4	)	(2.0	)	(4.4	)
WW		193	200	(3.4	)	(1.9	)	(1.5	)

TOTAL CONSUMER
US		1,537	1,476	4.1		4.1		—
Intl		2,007	2,028	(1.0	)	4.9		(5.9	)
WW	$	3,544	3,504	1.2	%	4.6	%	(3.4	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

		SECOND QUARTER
				% Change
		2019	2018	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	2,379	2,317	2.7	%	2.7	%	—	%
Intl		1,087	1,021	6.3		12.5		(6.2	)
WW		3,466	3,338	3.8		5.7		(1.9	)
REMICADE
US		801	918	(12.7	)	(12.7	)	—
US Exports⁽³⁾		62	104	(40.3	)	(40.3	)	—
Intl		244	298	(18.5	)	(13.5	)	(5.0	)
WW		1,107	1,320	(16.2	)	(15.1	)	(1.1	)
SIMPONI / SIMPONI ARIA
US		281	274	2.7		2.7		—
Intl		282	274	2.7		8.5		(5.8	)
WW		563	548	2.7		5.6		(2.9	)
STELARA
US		1,058	919	15.2		15.2		—
Intl		499	422	18.1		25.0		(6.9	)
WW		1,558	1,341	16.1		18.3		(2.2	)
TREMFYA
US		176	102	72.3		72.3		—
Intl		59	24	*		*		*
WW		235	126	86.5		88.9		(2.4	)
OTHER IMMUNOLOGY ⁽⁴⁾
US		—	—	—		—		—
Intl		3	3	27.7		27.0		0.7
WW		3	3	27.7		27.0		0.7

INFECTIOUS DISEASES
US		387	328	17.8		17.8		—
Intl		475	521	(8.7	)	(2.5	)	(6.2	)
WW		862	849	1.5		5.4		(3.9	)
EDURANT / rilpivirine
US		12	15	(15.8	)	(15.8	)	—
Intl		198	196	0.5		6.6		(6.1	)
WW		210	211	(0.6	)	5.0		(5.6	)
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US		344	277	24.2		24.2		—
Intl		191	215	(11.1	)	(4.6	)	(6.5	)
WW		535	492	8.7		11.6		(2.9	)
OTHER INFECTIOUS DISEASES
US		31	36	(16.6	)	(16.6	)	—
Intl		86	110	(20.8	)	(14.6	)	(6.2	)
WW		117	146	(19.7	)	(15.1	)	(4.6	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

		SECOND QUARTER
				% Change
		2019	2018	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	664	639	3.8	%	3.8	%	—	%
Intl		875	889	(1.6	)	3.9		(5.5	)
WW		1,538	1,528	0.6		3.9		(3.3	)
CONCERTA / methylphenidate
US		15	68	(78.6	)	(78.6	)	—
Intl		123	115	6.2		12.1		(5.9	)
WW		137	183	(25.2	)	(21.5	)	(3.7	)
INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA
US		506	438	15.6		15.6		—
Intl		312	282	10.4		17.2		(6.8	)
WW		818	720	13.6		16.3		(2.7	)
RISPERDAL CONSTA
US		81	80	0.8		0.8		—
Intl		101	108	(6.5	)	(0.1	)	(6.4	)
WW		182	188	(3.4	)	0.3		(3.7	)
OTHER NEUROSCIENCE
US		62	53	16.1		16.1		—
Intl		340	384	(11.5	)	(7.3	)	(4.2	)
WW		401	437	(8.1	)	(4.4	)	(3.7	)

ONCOLOGY
US		1,013	1,085	(6.6	)	(6.6	)	—
Intl		1,684	1,371	22.8		30.5		(7.7	)
WW		2,697	2,456	9.8		14.1		(4.3	)
DARZALEX
US		369	298	24.4		24.4		—
Intl		405	213	89.5		*		(13.6	)
WW		774	511	51.6		57.3		(5.7	)
IMBRUVICA
US		367	250	47.0		47.0		—
Intl		463	370	25.3		33.9		(8.6	)
WW		831	620	34.1		39.2		(5.1	)
VELCADE
US		—	—	—		—		—
Intl		224	280	(20.1	)	(16.1	)	(4.0	)
WW		224	280	(20.1	)	(16.1	)	(4.0	)
ZYTIGA / abiraterone acetate
US		198	486	(59.4	)	(59.4	)	—
Intl		500	423	18.0		24.5		(6.5	)
WW		698	909	(23.3	)	(20.3	)	(3.0	)
OTHER ONCOLOGY
US		78	51	50.5		50.5		—
Intl		92	85	8.8		16.2		(7.4	)
WW		170	136	24.7		29.3		(4.6	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2019	2018	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

PULMONARY HYPERTENSION
US	$	439	429	2.2	%	2.2	%	—	%
Intl		251	236	6.7		12.7		(6.0	)
WW		690	665	3.8		6.0		(2.2	)
OPSUMIT
US		203	180	12.8		12.8		—
Intl		146	131	11.5		18.1		(6.6	)
WW		348	311	12.3		15.0		(2.7	)
TRACLEER
US		41	71	(41.8	)	(41.8	)	—
Intl		62	72	(14.5	)	(10.9	)	(3.6	)
WW		103	143	(28.0	)	(26.2	)	(1.8	)
UPTRAVI
US		175	155	13.4		13.4		—
Intl		28	16	62.5		71.6		(9.1	)
WW		203	171	18.2		19.1		(0.9	)
OTHER
US		20	23	(18.2	)	(18.2	)	—
Intl		16	17	3.7		13.3		(9.6	)
WW		37	40	(9.6	)	(5.8	)	(3.8	)


See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2019	2018	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

CARDIOVASCULAR / METABOLISM / OTHER
US	$	902	1,101	(18.1	)%	(18.1	)%	—	%
Intl		373	417	(10.5	)	(5.7	)	(4.8	)
WW		1,275	1,518	(16.0	)	(14.7	)	(1.3	)
XARELTO
US		549	679	(19.2	)	(19.2	)	—
Intl		—	—	—		—		—
WW		549	679	(19.2	)	(19.2	)	—
INVOKANA / INVOKAMET
US		132	169	(21.2	)	(21.2	)	—
Intl		43	46	(6.0	)	(1.5	)	(4.5	)
WW		177	215	(17.9	)	(16.9	)	(1.0	)
PROCRIT / EPREX
US		113	156	(27.5	)	(27.5	)	—
Intl		70	80	(13.4	)	(9.6	)	(3.8	)
WW		183	236	(22.7	)	(21.4	)	(1.3	)
OTHER
US		107	97	9.3		9.3		—
Intl		260	291	(10.5	)	(5.2	)	(5.3	)
WW		368	388	(5.5	)	(1.5	)	(4.0	)

TOTAL PHARMACEUTICAL
US		5,783	5,899	(2.0	)	(2.0	)	—
Intl		4,746	4,455	6.5		12.9		(6.4	)
WW	$	10,529	10,354	1.7	%	4.4	%	(2.7	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

		SECOND QUARTER
				% Change
		2019	2018	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES SEGMENT ^{(2) (5)}

DIABETES CARE ⁽⁵⁾
US	$	—	129	*%		*%		—	%
Intl		—	226	*		*		*
WW		—	355	*		*		*

INTERVENTIONAL SOLUTIONS
US		366	323	13.7		13.7		—
Intl		385	344	11.6		17.3		(5.7	)
WW		750	667	12.6		15.6		(3.0	)

ORTHOPAEDICS
US		1,331	1,332	(0.1	)	(0.1	)	—
Intl		894	930	(3.8	)	1.5		(5.3	)
WW		2,224	2,262	(1.6	)	0.6		(2.2	)

HIPS
US		216	211	2.1		2.1		—
Intl		147	149	(0.7	)	5.0		(5.7	)
WW		364	360	0.9		3.3		(2.4	)

KNEES
US		218	229	(4.8	)	(4.8	)	—
Intl		153	153	0.4		5.4		(5.0	)
WW		372	382	(2.8	)	(0.7	)	(2.1	)

TRAUMA
US		407	394	3.3		3.3		—
Intl		265	281	(5.9	)	(0.6	)	(5.3	)
WW		672	675	(0.6	)	1.7		(2.3	)

SPINE & OTHER
US		490	498	(1.5	)	(1.5	)	—
Intl		328	347	(5.3	)	0.0		(5.3	)
WW		818	845	(3.1	)	(0.9	)	(2.2	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

		SECOND QUARTER
				% Change
		2019	2018	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES SEGMENT ^{(2) (5) (Continued)}

SURGERY
US	$	926	1,022	(9.5	)%	(9.5	)%	—	%
Intl		1,427	1,493	(4.4	)	1.5		(5.9	)
WW		2,353	2,515	(6.5	)	(3.0	)	(3.5	)

ADVANCED
US		396	402	(1.7	)	(1.7	)	—
Intl		633	603	5.0		11.2		(6.2	)
WW		1,029	1,005	2.3		6.1		(3.8	)

GENERAL
US		443	436	1.6		1.6		—
Intl		674	733	(7.9	)	(2.4	)	(5.5	)
WW		1,119	1,169	(4.3	)	(0.9	)	(3.4	)

SPECIALTY
US		87	184	(53.1	)	(53.1	)	—
Intl		120	157	(23.7	)	(18.2	)	(5.5	)
WW		206	341	(39.6	)	(37.1	)	(2.5	)

VISION
US		461	459	0.4		0.4		—
Intl		701	714	(2.0	)	2.2		(4.2	)
WW		1,161	1,173	(1.0	)	1.5		(2.5	)

CONTACT LENSES / OTHER
US		333	320	3.9		3.9		—
Intl		509	524	(2.9	)	1.5		(4.4	)
WW		842	844	(0.3	)	2.4		(2.7	)
SURGICAL
US		128	139	(7.7	)	(7.7	)	—
Intl		191	190	0.7		4.2		(3.5	)
WW		319	329	(2.8	)	(0.8	)	(2.0	)

TOTAL MEDICAL DEVICES
US		3,083	3,265	(5.6	)	(5.6	)	—
Intl		3,406	3,707	(8.1	)	(2.9	)	(5.2	)
WW	$	6,489	6,972	(6.9	)%	(4.1	)%	(2.8	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2019	2018	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT⁽²⁾

BABY CARE
US	$	186	186	(0.2	)%	(0.2	)%	—	%
Intl		651	727	(10.5	)	(3.2	)	(7.3	)
WW		837	913	(8.4	)	(2.6	)	(5.8	)

BEAUTY
US		1,251	1,248	0.3		0.3		—
Intl		1,041	945	10.1		16.3		(6.2	)
WW		2,292	2,193	4.5		7.2		(2.7	)

ORAL CARE
US		306	314	(2.5	)	(2.5	)	—
Intl		450	458	(1.7	)	4.9		(6.6	)
WW		756	772	(2.0	)	1.9		(3.9	)

OTC
US		991	919	7.8		7.8		—
Intl		1,160	1,219	(4.9	)	1.4		(6.3	)
WW		2,151	2,138	0.6		4.2		(3.6	)

WOMEN'S HEALTH
US		6	7	(3.7	)	(3.7	)	—
Intl		472	516	(8.6	)	1.3		(9.9	)
WW		478	523	(8.5	)	1.2		(9.7	)

WOUND CARE / OTHER
US		234	238	(1.5	)	(1.5	)	—
Intl		114	125	(8.9	)	(3.9	)	(5.0	)
WW		348	363	(4.0	)	(2.3	)	(1.7	)

TOTAL CONSUMER
US		2,975	2,912	2.2		2.2		—
Intl		3,887	3,990	(2.6	)	4.3		(6.9	)
WW	$	6,862	6,902	(0.6	)%	3.4	%	(4.0	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

		SIX MONTHS
				% Change
		2019	2018	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	4,542	4,317	5.2	%	5.2	%	—	%
Intl		2,175	2,063	5.4		12.5		(7.1	)
WW		6,717	6,380	5.3		7.6		(2.3	)
REMICADE
US		1,575	1,834	(14.1	)	(14.1	)	—
US Exports⁽³⁾		138	246	(43.9	)	(43.9	)	—
Intl		496	629	(21.2	)	(15.5	)	(5.7	)
WW		2,209	2,709	(18.5	)	(17.1	)	(1.3	)
SIMPONI / SIMPONI ARIA
US		544	498	9.1		9.1		—
Intl		543	568	(4.4	)	2.2		(6.6	)
WW		1,087	1,066	1.9		5.4		(3.5	)
STELARA
US		1,940	1,571	23.5		23.5		—
Intl		1,022	831	23.0		31.0		(8.0	)
WW		2,963	2,402	23.3		26.1		(2.8	)
TREMFYA
US		344	168	*		*		—
Intl		108	30	*		*		*
WW		452	198	*		*		*
OTHER IMMUNOLOGY ⁽⁴⁾
US		—	—	—		—		—
Intl		6	5	23.6		24.0		(0.4	)
WW		6	5	23.6		24.0		(0.4	)

INFECTIOUS DISEASES
US		744	661	12.5		12.5		—
Intl		964	1,018	(5.3	)	2.5		(7.8	)
WW		1,708	1,679	1.7		6.5		(4.8	)
EDURANT / rilpivirine
US		24	29	(17.3	)	(17.3	)	—
Intl		397	392	1.4		8.6		(7.2	)
WW		421	421	0.1		6.8		(6.7	)
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US		659	550	19.9		19.9		—
Intl		399	420	(5.0	)	3.4		(8.4	)
WW		1,058	970	9.1		12.7		(3.6	)
OTHER INFECTIOUS DISEASES
US		61	82	(26.0	)	(26.0	)	—
Intl		168	206	(18.6	)	(10.7	)	(7.9	)
WW		229	288	(20.7	)	(15.1	)	(5.6	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

		SIX MONTHS
				% Change
		2019	2018	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	1,387	1,263	9.8	%	9.8	%	—	%
Intl		1,780	1,824	(2.4	)	4.1		(6.5	)
WW		3,167	3,087	2.6		6.4		(3.8	)
CONCERTA / methylphenidate
US		112	134	(16.4	)	(16.4	)	—
Intl		239	222	7.3		13.9		(6.6	)
WW		351	356	(1.6	)	2.5		(4.1	)
INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA
US		989	838	18.1		18.1		—
Intl		619	578	7.0		14.7		(7.7	)
WW		1,608	1,416	13.6		16.7		(3.1	)
RISPERDAL CONSTA
US		158	162	(3.0	)	(3.0	)	—
Intl		203	222	(8.4	)	(1.3	)	(7.1	)
WW		361	384	(6.2	)	(2.0	)	(4.2	)
OTHER NEUROSCIENCE
US		128	129	(0.4	)	(0.4	)	—
Intl		719	802	(10.3	)	(4.8	)	(5.5	)
WW		847	931	(8.9	)	(4.1	)	(4.8	)

ONCOLOGY
US		1,975	2,018	(2.1	)	(2.1	)	—
Intl		3,240	2,749	17.9		26.3		(8.4	)
WW		5,215	4,767	9.4		14.3		(4.9	)
DARZALEX
US		721	562	28.5		28.5		—
Intl		682	381	78.7		93.0		(14.3	)
WW		1,403	943	48.8		54.6		(5.8	)
IMBRUVICA
US		716	477	50.2		50.2		—
Intl		898	730	23.1		33.0		(9.9	)
WW		1,615	1,207	33.8		39.8		(6.0	)
VELCADE
US		—	—	—		—		—
Intl		487	593	(17.9	)	(12.9	)	(5.0	)
WW		487	593	(17.9	)	(12.9	)	(5.0	)
ZYTIGA / abiraterone acetate
US		383	893	(57.1	)	(57.1	)	—
Intl		994	861	15.4		22.6		(7.2	)
WW		1,377	1,754	(21.5	)	(18.0	)	(3.5	)
OTHER ONCOLOGY
US		154	86	77.7		77.7		—
Intl		179	184	(2.5	)	5.3		(7.8	)
WW		333	270	23.2		28.6		(5.4	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2019	2018	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

PULMONARY HYPERTENSION
US	$	869	790	10.0	%	10.0	%	—	%
Intl		477	460	3.7		10.7		(7.0	)
WW		1,346	1,250	7.7		10.2		(2.5	)
OPSUMIT
US		375	329	14.2		14.2		—
Intl		279	253	10.3		18.0		(7.7	)
WW		654	582	12.5		15.8		(3.3	)
TRACLEER
US		102	139	(26.3	)	(26.3	)	—
Intl		118	144	(18.7	)	(14.6	)	(4.1	)
WW		220	283	(22.4	)	(20.3	)	(2.1	)
UPTRAVI
US		351	279	25.9		25.9		—
Intl		50	32	53.1		63.0		(9.9	)
WW		401	311	28.7		29.7		(1.0	)
OTHER
US		41	43	(8.4	)	(8.4	)	—
Intl		31	31	4.1		15.1		(11.0	)
WW		72	74	(3.4	)	1.0		(4.4	)


See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2019	2018	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

CARDIOVASCULAR / METABOLISM / OTHER
US	$	1,849	2,204	(16.1	)%	(16.1	)%	—	%
Intl		771	831	(7.2	)	(1.5	)	(5.7	)
WW		2,620	3,035	(13.7	)	(12.1	)	(1.6	)
XARELTO
US		1,091	1,257	(13.2	)	(13.2	)	—
Intl		—	—	—		—		—
WW		1,091	1,257	(13.2	)	(13.2	)	—
INVOKANA / INVOKAMET
US		286	373	(23.2	)	(23.2	)	—
Intl		92	90	2.6		8.9		(6.3	)
WW		379	463	(18.2	)	(16.9	)	(1.3	)
PROCRIT / EPREX
US		261	345	(24.3	)	(24.3	)	—
Intl		148	167	(11.7	)	(7.3	)	(4.4	)
WW		409	512	(20.2	)	(18.7	)	(1.5	)
OTHER
US		211	229	(8.2	)	(8.2	)	—
Intl		531	574	(7.5	)	(1.4	)	(6.1	)
WW		742	803	(7.7	)	(3.4	)	(4.3	)

TOTAL PHARMACEUTICAL
US		11,365	11,253	1.0		1.0		—
Intl		9,408	8,945	5.2		12.5		(7.3	)
WW	$	20,773	20,198	2.8	%	6.1	%	(3.3	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

		SIX MONTHS
				% Change
		2019	2018	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES SEGMENT ^{(2) (5)}

DIABETES CARE ⁽⁵⁾
US	$	—	246	*%		*%		—	%
Intl		—	448	*		*		*
WW		—	694	*		*		*

INTERVENTIONAL SOLUTIONS
US		709	627	13.2		13.2		—
Intl		774	680	13.7		20.0		(6.3	)
WW		1,482	1,307	13.4		16.7		(3.3	)

ORTHOPAEDICS
US		2,649	2,639	0.4		0.4		—
Intl		1,779	1,873	(5.0	)	1.1		(6.1	)
WW		4,428	4,512	(1.9	)	0.7		(2.6	)

HIPS
US		429	420	2.1		2.1		—
Intl		295	303	(2.3	)	4.2		(6.5	)
WW		725	723	0.3		3.0		(2.7	)

KNEES
US		441	457	(3.5	)	(3.5	)	—
Intl		299	312	(4.0	)	1.9		(5.9	)
WW		741	769	(3.7	)	(1.3	)	(2.4	)

TRAUMA
US		824	801	2.9		2.9		—
Intl		533	570	(6.5	)	(0.5	)	(6.0	)
WW		1,357	1,371	(1.0	)	1.5		(2.5	)

SPINE & OTHER
US		955	961	(0.6	)	(0.6	)	—
Intl		651	688	(5.4	)	0.6		(6.0	)
WW		1,606	1,649	(2.6	)	(0.1	)	(2.5	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

		SIX MONTHS
				% Change
		2019	2018	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES SEGMENT ^{(2) (5) (Continued)}

SURGERY
US	$	1,927	2,015	(4.4	)%	(4.4	)%	—	%
Intl		2,821	2,923	(3.5	)	3.0		(6.5	)
WW		4,748	4,938	(3.9	)	0.0		(3.9	)

ADVANCED
US		800	795	0.6		0.6		—
Intl		1,209	1,176	2.8		9.5		(6.7	)
WW		2,009	1,971	1.9		5.9		(4.0	)

GENERAL
US		868	859	1.0		1.0		—
Intl		1,339	1,437	(6.8	)	(0.4	)	(6.4	)
WW		2,208	2,296	(3.9	)	0.1		(4.0	)

SPECIALTY
US		259	361	(28.3	)	(28.3	)	—
Intl		273	310	(12.1	)	(5.4	)	(6.7	)
WW		531	671	(20.8	)	(17.8	)	(3.0	)

VISION
US		907	899	1.0		1.0		—
Intl		1,383	1,389	(0.5	)	4.7		(5.2	)
WW		2,290	2,288	0.1		3.2		(3.1	)

CONTACT LENSES / OTHER
US		654	629	4.0		4.0		—
Intl		1,011	1,022	(1.0	)	4.4		(5.4	)
WW		1,666	1,651	0.9		4.2		(3.3	)
SURGICAL
US		253	270	(6.1	)	(6.1	)	—
Intl		371	367	1.0		5.5		(4.5	)
WW		624	637	(2.0	)	0.6		(2.6	)

TOTAL MEDICAL DEVICES
US		6,192	6,426	(3.6	)	(3.6	)	—
Intl		6,756	7,313	(7.6	)	(1.6	)	(6.0	)
WW	$	12,948	13,739	(5.7	)%	(2.6	)%	(3.1	)%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful
⁽¹⁾ Operational growth excludes the effect of translational currency
⁽²⁾ Unaudited
⁽³⁾ Reported as U.S. sales
⁽⁴⁾ Prior year amounts have been reclassified to conform to current year product disclosure
⁽⁵⁾ Reflects LifeScan divestiture October 2, 2018

GRAPHIC 4 jnjlogoa06a02a01a01a01a26.jpg begin 644 jnjlogoa06a02a01a01a01a26.jpg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end GRAPHIC 5 overallfinancialresults.jpg begin 644 overallfinancialresults.jpg M_]C_X 02D9)1@ ! 0$ 7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH \X^.WQX\/?L^^$[/7->L]7U:34+Z+3-.TC0;(W=]?W4@8I# M#&" 6(5CR0.,9R0#YCJ'[>W@6T^$>G^.[;PUXSU0W7B(>%)/#%GI*G6K74]C M/]FEMGE7YP%'"LQRR@9YP_\ ;O\ "\?BSX3Z7;W7P[\2^/K"WU>&ZFE\%7P@ MUS1BH;;>V<>QO/D4G;Y?'W\]!D?(GB[PO\7_ !)^R_H0\2:9\8-9TS3?B=:W MNC-]B9O&]OHZ6TH:9E3<4E61FV/(>"1SM*U$7S^C1HTO M=MV?WI2?Z+S\M4S[5\%_M?:%XA\*^+O$OB;P-X^^%>@^&;5+N[OO'V@G3DF1 MBPQ!AW,K J!M SET R36;\)_VY/!?Q2^(.F^#+CPSXU\":SK$#W.B_\ "9Z( M;"+6(T!9FMGWMN 4;OFVY!&,GBOF[1_A_KWQ<^ ?Q-\)^&--^/NH:\KZ9J]I M;_'D!8+Q[:Z$OV6U=B /,"$.#Q]S)%>Y>!?C[XW^.OQ0T#2+;X#>)O!FB6NG MWB:WXD\;Z<+"73Y)(PJ+I[Y/GAF4AMN,C83M YUUN^57TVVZ-WOZZ?+^\C'I MKIY[]5I;TU\[_P!UC];_ ."BGP[TC6-5^S^%_'VM^$-)NGM-0\>:1X<>YT"V M=#MD+7(;<51N"RH0<@C((-=_J/[6WP_TSXX>#?A?+=W+ZOXNTA=9T;5(DC;3 MKF)C)L02A]V]Q$Q7Y-IX&[) KY;\"^-OB1\#?V>;[]GJY^ OC?Q)XLM;.^T; M3=!G-*-KKK%=5NURR;LNC5E M9=Y69;5U+H]=.SYHI7?5:N[6Z5T?3'CK]N3P9X$\/:WJLOAOQ;K+:5XS/@0Z M?H]A#/=W6H^5Y@,$?GC?&P(4'?&ND'3KY[4ML%PB;F#1[L+G.+_AAXKN/%EK M\=[3Q1JNBZ)HL\]Q-!#:IYT]O'CYXF=&"N&V$D#?WKZ?^%>K>*/V@_VKM+^) M[_#?Q1\.O"'AGPQ=:/&_C2P%CJ%_=7$\;E5@W,1&BQD[\D$L1WJH1V4G?OY? MNXRO\YMK\-R:KY=8Z=O/WY1M\HJ_X['J_P <_P!J+PM\"=4TC1+O2?$?C#Q9 MJT;SV7ACP?IC:CJ,L*$!YO+!4*B^K,,X.,X..67]NKX>?\*9\7_$.33_ !): MKX1G@M==\,7NG+;:UI\LTB1HDEO*ZJ,F0'._&%;!)!%<=\>/^$T^!O[3,GQB MT3P)KOQ$T+5O"!\-RV_ANT^W7NF74=P9H9#:AT:2%RP#;&&-K$D<9^:H_"OQ M5_:P\,_M+ZIK'@B3P/XZU_0= BLO!UY'+;7-VMK*)3.!.$^5S&R+G."=A.5R MV=-IJ\O._DE)]-W>*]?>NM$;/SO:_I9M_^ VW:/T5\6?&+1O!WC[P M!X1O;6_EU+QK+=1:=+!&AAB-O;F=_.)<%05&!M#<]<#FN<\,_M1>#?%7[0?B M+X.V2:B/$^B6INIKJ6!!8S%5A:2&*0.6:1!<1%E*C&>IKYZL_B5XN_: ^.WP MI\4P_!WX@>"M"^'%CJVIZQ)XJT9K5[F::R,,=O9J&+7!+;ONKD_+\HS7CGP] M^&7[1/@?5/AO\8M:\'Z/-92>,+C7M2TW2;/49/%*0ZJPANDNH#'LV1Q",[0, MKY2>AK2,?WL8RV=_O;Y8_+=OR7F<[;5+F^TDK^JNY?ARKY]TSZ6\1?\ !1;P MKH.O>,+&+X7?%36].\)ZG//%GA/6]-@U2W\1>&M%6?3XHIF A66666/RY&W M+A",_.O)M#_ &@/%NBZGX\TV[7X@:K=#X?_ &^ZT_2O%6E$ MHTFR./8SO,C,JRJ65Q&$QW'T+^TYH%SX_P#V +;3/!'@77].9[?1DL_"3Z9< M?VA8QQ75N# \!7S,QJAR<'(7=D@YJ*:YJ<.9ZMT[_P#;RU_X%MK-/H;U%&-5 MQCM[_P#Y*]/^#WNK=;69_P#@HMHT.LVNBCX'_&N77KBR.H_V/%X21KV.V$IB M\UX?M&X(6& V,'USQ6]XN_;JT3P7X?\ E]?_"SXI-J_C*2^CT[PO#X>0ZPA MM2OF&2U,X8 JV]=N[*@DXKPK]L[POK*_M8:-X@.D?',:#_PA,5A_:GP4MG^U M?:?MLS^3/+C;LV_,4SG.PXQ57Q-\)M=^.VI_LPV.G-\_%6WN_N3E_DOO(TC*SVM?Y\G-^?Y M'US\ _VF/#O[04GB*ST[1/$OA/7_ ]+#'J?A_Q;IAL+^V$JEH7:/04445!04444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110!X]\3-076/C9X'\,7LOV/2;72=4\3/=-(%1;BW M-O;PLV3R(Q>22<\!DC;JH->._LE^'-$^&'Q)O-#O_#VG#Q5J=NWV?QEX=OC< M6FO11V>GR2S7).QGGE,JW 9UE"F:8+,2S%_HWQCX%GUCQQX0\4:<;9;W2'N+ M.[2Y+ 7&GW" 31@@'YA)%;R $8/ED<;MPQ_AO^S?X"^%'BC4?$'AW2[B'4;I M3%%]JOY[F*PA*QAH+2.1V6WB/E1_)& ,(B_<1%5T_==_)W]=;?@TM-[.][)# MG[VGI_7WIOYZ6NS@?BY\8-<\!_$/Q=;^'-#\/R:O%;^%+:&^O;9Q-.+_ %2Y MM62:1'!9(URT8_A:1R=V[%>@?!7QMXE\37'CC1O%K>&-<_LHW^C6,X&[KWPE\*>)M:NM6U+2OM.H71TYIIOM$ MJ;C8W#7-IPK@#RY79N!\V<-N&!6OH?A+2?#>H:Y?:=:?9[K6[P7^H2>8[>=. M(8X0^&)"_NX8UPN!\N<9))<;)/F\_P#VVWY2^]?)SM)W7E^5G^)\7?"SQ)?M/_A17@4W' MAZ=O#\4DWA_5[O7=,>2:5C;7MRTKSRC+\[FFD.ULJ"1@#:N*]Y^SWX O[&[L MY] \RVNK35+&9/MEP-T.HSBXO5R),CS)5#9'*XPA4<44VHVOYI^G*U'[F[>B M-547M.?IS\WXN_WJS];[=?$O#?BQ?#'QCUF)]*T_4$U#XD& SW=MYL]H$\)1 M3>9;'/R2'RMA;G*2.N/FS3+S]I_XA^'OARGBW4[7PQ>1^(? VI>,="L[.UG1 MM.>VC@E2VNG,[?:E9+E 946##1D;?G&WZ$C^$/A&'Q NMII.-375?[;$_P!I MF/\ IGV+[%YNW?M_X]_W>W&W^+&[YJYVQ_9A^&VGV>M6<7A^9[/5M/GTF:UG MU2\FBM[*8YEMK1'E*V<3';E+<1K\B]D^D4ONC;\[-/I;S:,J?+'DYE MHK7\_>;_ "^_RW.(F^+GQ5TAOB#HTVFZ'X@\1:/I&DZS8?V/IMP!##>3W$Z:W2W>0")XVGQL5$8BO0/@/\1+[XB>%]1GU/4M-U34-/U&2QFEL=(O M='D7"(X6>PO,S6TFV0?(S.&4HX;#[5UO$GP;\'^+IM9EU72/M,VKVEI8W]N MI-1NKJ[U"10 1<7$LK23;E5$/FLX"(J@#:NT37,]-'^&J_)7\WU;Z9V?*NZ_ M^1U7SE\DNQB?M#?%R_\ A5H_AN+2HR-4\0:L-+@NSHMWK*VH$$UP\ALK0B>X M^2!E"HRX+AB0JG/G.M?M/^+_ 3\,?#?COQ%X=@@TZ>6]TG4-,N+"YTN^FO( MS)]FO(([MD:*UD6%I'25-\4;^8SE8G)]^\;> ]%^(FC+IFMV\\L$ M36=S;RK]V2&X@=)8GP2-R,I*LRGAB#C:+\$O!6@7&ES6FBAGTVSN;&V^U74U MR%2X??5[ZM)&K:TM_6_P#P-/*V MEV<"GC;XLZYXLN?">BWG@R/7/#VBV.I:Q/?:9>&UU*YN7FVP6Q6XW6T:K;L# M,WV@DN#Y?RD-A>)/VE/%-K\9]1\/:+H5QJ>DZ+K-AHM]IUKX6U2]FN?M$4,D MMTNIP@VELL*W*,8IE+,L+DLF],=[>?LN?#>^TO2--ET:^%EI=@-*BBCUR_C$ M]D&++:716<&Z@4LP$4_F(H9E"@,0=S5?@CX,UKQ=;^);K2ICJ,+P2F&&_N8K M*:2#_42S6:2"WFDCPNR22-F79'M(V+C5-,ZQ\;OB@L>K:M&_A.V\-CQ=<^#;:V%A=27R$RO;P7K2"X56VRF+?; MJ@W(KN)D)VKZ!^S;J&O:Q^RUX%U#Q+JRZYK%YX;M[F6^\N1'E#P!E,ADDD9Y M,$;I"WSMEMJYVBM\.?V:=$\.>)M:\2Z]:KJ.MW/B+4-:M%34;J2RC\]W$@_#CPC;^%] MKBUT*W5D@M9[V>Y\I&S^[1 MI79E09PJ [5& H &*Y^5RPSA+XI1C\GRZK_P)MW^6R1HVE5YELF__2G9_=9) M?/=GRK^RC\$XI/AS\*==F^ OPB6/^R].O?\ A*5O VL9\I'%UY9TD?Z1G#X^ MT<-_RT/6N:\-_##3?&W@+QO#I?[/O]L^-+[Q%XBAL/B)Y>C6WV>Y.J72PW7V MLW(OH_(;;\R1%QY7R!OES].>'?V8?!'A./38=(N?&5C:::(UM+*/QYKOV6)( M\;(Q ;SR]@ V%=N.,8XKT#PKX2TGP5I3,UQ,\\S9 M8D_-)([8S@9P *ZJDE.3?>_P"-NVWRM_E*;2LNZ?W*7^:WO_G\Q^/?A"^O M>-/%&LZCX)\*_'VRCAL=-N5DU&*/Q!X?DC@59X;-)HS"KD2+=C-Q;29E/+8C M-==X#\2VS>-O@WJ^@ZIJFIZ/XL\*3V5S-K1!O;HVR0S6TUS@ >>H>Y5R!RTI M]!7H?B_X!^"_&VOW6MW]GJ=GJ=Y"D%[/H>NW^E?;HT!"+!(PI/#2< M#C.<6^N[?Z2O]][+2Z;NV[7(<4MMDK>>Z_*UWKTVZ'?T444B@HHHH **** " MBBB@ HHHH ^*/V]/A'X8\?>*M'G\2WFK>,]:O-'N-+\&?#/299('EU9FW?VF M94E4(D2D;WD'EJJ\DG"MY1\2_A%'XN\>O\/_ (P^*KW69_AW\'8M9TZ1=3EM MT_M9&D2;4%<%3(Z&- &?.006!YK["^-'[&'P=_:&\50>(_B#X1;Q#K%O:K91 M7#:M>VX2%69@@2&9%^\['.,G/)IGB[]B?X)^._#7A'0->\!VFHZ7X3@6UT>. M2[N0]O".1$TBR!Y4R,[9&8=>.:SC%J'+>VK^5U-)KS3E?Y)72BC7F7M%*U[) M?G%M>C4;?-MI\S/DG]H[3/%7Q"_81^%7Q!\0>,M;4Q:=X=\[08Y%6"_NI;J! M6N[I\;YF*%2$)VAOFY-:_P"W]\-]5\5_&:76)=,TOQ]I&E^#9;FVTB7QM_8= MQX4GCDD9M9,"L&F3&P94')CVG&%S]N^.OA#X0^)'@>+P=X@T2*Z\,Q-;O%IL M$DEM''Y#J\(7RF4J%9%PH.,#&,<5S?QB_99^%?Q_UC1M4\?^#K/Q'J&D<6EQ M-+-$RKNW;'\MU\Q,\['W+R>.36M;]XWRZ>_*7HI12^]._56TLUI;"DN1)2U] MV,?G&3?W->M];IJ]W_LL^*-8\:?LW_#/7?$$DD^M:AX>LKBZGE.7F=H5)D;W M;[W_ *O4JAM+2#3[6&UM88[:VA18XH84"I&@& J@< 5-6E62J5)32LF MV33BX0C%]$%%%%9&@4444 %%%% 'FG[27A7_ (3;X'^+M&?QLWP[M;FS/VOQ M*@YL[=6#2G.],!D5E)W# 8U^?NK>!I?A'^S=\8_%/P[?7?AS\'?%5YH>F:'; M7EW.;A[1KB.&]U15E9GMTN$E.W<0S(,E5!05^D/Q3^%?ACXU>!]0\'^,M.;5 M_#M^8SUNKZZO([J%22JD3ROMP6)!7!S@YX%1%:W\[)72O?Q'X"_"J'P1\8/CW\&?A?XEU/PAX-@TS1+RRN M+2[^WOI%S<)(;CR/.+['E1?<".66>69P, O+*SNP )P"V!DX R:9;_ +._PZM_ ?B?P6?"]O<>%_$M M]<:EJNFW4LLZ7-S.X>23+N60EU5AL(VE05VD5H MHNSB]K2O_P"2N-^FK=I/;KK?4^7O^"=&@S> /B1\9?"%SX>NOAF;5],O+;X; MR:R=8ATR.2!LW*7>Y@YF;EE&"NU0<\8^Z*\T^"7[-OPV_9STW4+'X=>%;?PY M#J$BRW;I--<33E00H:69W22^[[_P _NV6<8M7_ M *_R_K>[NV4445F6%%%% 'S=^VY\!=<^.'@S1_[(UK2])M]%>[NKMM8FEBAB M5[=D6\4QHW[VW/[U 0/F'WTZUD_LP_'W0_$7CS5_#VH6NJQ^,_$LTVL2WEU$ M@MML=O:M#9J?,+B6*RGLW<&-4WR2X.[<*^D?%GA72_'/AK4O#^MVOVW2-2@: MVN[;S'C$L3##(60AL$<'!Y!(KG]/^"_@S2_B9>?$"UT18?%EW ;>6^%Q*4VE M8U8K"7\I79885,BH'*QJ"2 !13M&4F]G^?\ 27GYM:!+WDNZ_K_/R]'J4_VA MO%&M>"/@1\0?$'AQ"^O:7H5[=V.U-Q$R0LRMCO@C./:OD/X=?LX_!3P5I'P0 M^*UK\3-4\.>.O$%[92S>*CK,T\WBFXFBWRV"".XKP[P;^P[\"_A_\1E\=:!\.=,T[Q,DK3Q7"RS/#!(3 MG?%;LYAB8'H40;>V**?NU')_W=>JLW=?.^OIJFM J>]3Y5_>TZ.Z5F_2WXNS M1\>WGC'XM_"BU_:%^(O@KQAIFC>&/#OQ2E:]\/W&C)+_ Y=^'O-T;Q=JO\ ;>M6 MWVVY7[7>;HG\W<)-R?-!$=J%5^7IR<\QX^_8C^!_Q0\::KXM\4?#ZPU;Q#JE ML+6[O9+BX0R*%"!@J2!5D"J )5 <8&&I4UR*DG]GE_",5;S3:EOM=-=C1N$I MSDU\3?W.3?R=GNOQ/ /C?\4/CQJ?Q.^/$'@3XD67A#P[\._#NG^(([.XT&VO M7N':TEF>W61QE%?RW)9@Y!5 NT%LZTGQZ^+/Q=^*7@3POX5\9:#\.8D^'UEX M[U6?4-*2\75))2 ]L [J8X!U9T(=<]3TKZ>X\:7$FBM)/XRTV'2-= MD>]N"U[:Q0O#&A)D^0B.1QN3:QW9))P:^9_VIOV'_$OQ&\8?#K5_A]:^ K_2 M/!^E+I=GX>\=P7+06_ED>5*)K<&:?: H\F=FCX)*L6:I^%X66 MSMK;5F=G)7OK;TO\'YVGKO9Z7>AX_KW[:_QBF^ ?P(@TJ_U>Z\8^.EU6XU#Q M!X9\+6^M:AMM;@HB6UCF*%\J1N)QA5SUYKZT_8I^*/Q'^)_PMU"7XG^'M9T; M7M+U.2P@O-=T-M&N=4M0B-'=/:DE8W.YE81DH"IP:H^"OV'_ +-^S3X*^$_ MQ+TNS\P?"GX0^#O@?X/@\+^! MM MO#NAPNT@MKI& MLE!K3O\ C]_?RV6AV%%%%8EGPK^SW_P3A_9V\)-;^'GVW6M8\,Z9J M%]<_VWJ,?G3RVL\0_![]GCXN_%A]3\7^.?AC;W=C;^#O^%A:K!=:NUT[>3=+6W7_@_E:[\CWC_AUQ^S%_T3/_RO MZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFO*_P!G?_@HWKOQ2F^(&AZH_@W7]>)M-U3PG;ZE#89@7FUN(KU(Y2X)5MR':5) (/-=-\,_VNOC):ZO\ "35_ MBCX4\'VG@/XEV@&FS>&;BX>_LKDVHG1KA96*E) K$(F2@8!G)7YJ:Y=_+\6T MOQBT1TTUW_!)O\))_P#!T.N_X=.44!OF'3!-27_[07[2'C[5/C6Z?G[R^\N,>:2BGO:W9WO:W_@+ M.T_X=,O&MO/>VOB37AJ,]C!81K&5>\2W1YGN':0J1$ B\=N M*[GPG_P40\2_$3X%:)J'A;P]H&I_$K5_&*>![1VEN8]$EN6C\T7H#JLX@*<^ M6VV0>O&#KR.[C'6SM\VU'\VE_P ,S)27*I/1-7^5F_R3?_#H]'_X=D?\.N/V8O^B9_^5_5/_DFC_AUQ^S%_T3/_ ,K^ MJ?\ R37,?&;]JSQ]X+^%WA/7OAQXC^'?C1%\*Q^(-2FUJWU'^U-3A6/+W$.G MVB-]FC;:27EDV*Q93M"$G&D_:HU&T^.-A\0+V75(_";? G_A-)O"L-\YMOM! MNE?(3.SS-I\OS"N<>W%4_=1Z!_ MPZX_9B_Z)G_Y7]4_^2:/^'7'[,7_ $3/_P K^J?_ "37D7[+G_!2S6/C#\:O M#_@S7T\'ZG;^*(IVL8?"<>I17>D2QQ-*(;QKN)(YBRJ5W0' 923P17<_LS_M M>?$?XI?&9_"_CR#P'X.6?[2(?"$ZZI9>)+Z^5-S>2PPIW<8*U7 M*^91[IO[M_RZ?JB'))-]K?B=)_PZX_9B_P"B9_\ E?U3_P"2:/\ AUQ^S%_T M3/\ \K^J?_)-?55%04?*O_#KC]F+_HF?_E?U3_Y)H_X=)-;^'GVW6M8\,Z9J%]<_VWJ,?G3RVL7W@O\ :J@O/B;J'CC0 M+FZN;IM*\2:7J$DV@RVS7]M'9VLEO&\D=M&\K[!+W:3P;I_Q??Q)XB?7KKQZNE/I7]H3?V=_9KZQ_9HM/L)8P M K%A_-""4R#)?!*EP]_E\W;YMI?==VOY2WLKDO=O;6W^3?Y+3KJKV3=M+_AU MQ^S%_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\ Y7]4_P#DFO5_VB-%\8^)/!^E M:3X-L+B^GNM8MAJ'V;7Y=#:.S3=(Y-Y#F:-69(T8PJ[[9&PO4CPS7OB%<^&T M\/\ PRMM-\6Q:Q<>)I+#Q#IND>)]0UB]G0:8UY'%9:I>2PRQI)^X!D+0",K* M,J/G:4[I][V_+7TUZ7>FPWI;TO\ GIZZ=;+5:FY_PZX_9B_Z)G_Y7]4_^2:/ M^'7'[,7_ $3/_P K^J?_ "36UH.EZ?XD\!ZGIDGC?QMX"T+PYK377BG2_%6L MDZI96PMA*MJ-6CN6DCMV+17'GK8B[D3K_ -FH:L^@^))Y)];G\'3Z MN\GA5O$ES-2&Y?AYOT73_#.AZA;6W]MZB/+GN+K M5HYGW"XW'>&A1BS.\1V/CY8;L4E(=/@FN+47'B,2+J,#QS.K6UP)427S(B#'^ M]!D(0%V=B7;OJN2Y78E.Z/E7_AUQ^S%_T3/_ ,K^J?\ R31_PZX_9B_Z)G_Y M7]4_^2:^JJ*D9\J_\.N/V8O^B9_^5_5/_DFC_AUQ^S%_T3/_ ,K^J?\ R37J MWQPT'3KJ.PUSQ7XYU+PKX$TB*5[VPTF_N=,FOKJ0HEN3=VTJ3D+F15MX_P#6 MO*GWBJJ?'_ ]CXQ\::[X \ ^,]7\5Z1I#:3K6O&!=5GLM6N+9+V*'38;N[MW M2;S([><-(N_W^>GW7:3[-]BU_PZX_ M9B_Z)G_Y7]4_^2:/^'7'[,7_ $3/_P K^J?_ "37JO[.?BK4=>^$YEUS49]0 MN](U/5='?5+[:)+B.SO9[>.:0J "Q2)2S #+;C7AG[/_ (@\2Q>*?AUJNL:O MXDB?Q0E^+O6M>U6XN-(\322(]Q;G3K)W/V(*J&0*\-H?+4HHEZBOM-+^K[?? M;_*^H.\4[[IV^YV?W&]_PZX_9B_Z)G_Y7]4_^2:/^'7'[,7_ $3/_P K^J?_ M "33YE\3_!7XI^&I=1U?Q5J<=[!?IJ^NZQ?O/I6O7K6[7$-M96 N)18NK1R; M3Y<*;8S'NE9UJ#X:WFN>&X_@'XMG\4>(=;U/XB,8O$-O?:C-<64K3Z=/?*\- ML[&.U\IX0JB!8P49@P8X((>_MTLGZN]OR\MT[682]W1]F_DM6_E_FKW1P?QP M_P""HW9 M!! (] _X=J_M+?\DZTC_L<_"?_ *D.G5ZK2 ^5 M?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S% M_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\ Y7]4_P#DFO6?BEXBO;KXB?#WP+8W M-U8)KH75FYCD^QV2HS1*XY3S)IK96(.=GF 8+9'-:F_CK3_ -J;P>-5 M\5Q2>%M2T_5Q9^'--M6@BC$7V MG]?U_7GH<7_PZX_9B_Z)G_Y7]4_^2:/^'7'[,7_1,_\ ROZI_P#)->Z_%;PG MJ?C'P[#9V.KZGIEG%<"YU"VT.4V]_J,"*S?9(;D31&V9W\O,@<':"NY=Q8>% M:!X@\3Z;\#?B#>#4-:L/$G@#5[K5;'1-;U&2XOK:TCB6XCL;ZX\QUO%E@=\/ MYDRJ)4_>&2'/K<:S>>$ M[NYBFT]_[>1=*O+&?3EBMM-6Q\W(NWU%TD\[R>(R?WV 4KV+X ?$3P_XQ\*K MINE^*+OQ3JNGQI/?WU]:7-LURTS.PN(!.BE[9W641/'NBVIM1B$XTY7UW6_E MY?+K^JU(NM&M4^O]?A_G=+R?_AUQ^S%_T3/_ ,K^J?\ R31_PZX_9B_Z)G_Y M7]4_^2:^JJ*D9\J_\.N/V8O^B9_^5_5/_DFN_P#V/?"VE^!_@BOAO1+7[%HN MC^)O$VGV-MYCR>3!%KU_'&FYR6;"J!EB2<N>E;M[^QC\/K^\^)WFG51HOQ",<^L>'X[E$L8[Q"&%[;J$WQ7!8!BP? M!."5.!CEOV9?V>_"^M?LV_"C4+C5?'$=Q=^$M)N)$M/'VNVT*LUG$Q"11WJI M&N3PB*%48 KTO_AFGPC_T%_B!_P"''\0__)U*RM;U_'5_CKZZESB]-_96E^''PO\ B'IND^.OB%\0]7UK0;O3[*#QIXF>]CA9X65(XD.R M),MM&]AD#C< 3GE/V8?V%/#_ ,-=/^'GBGQ3<^)M3\6Z'HD,4/A_6]:^W:7H M5Y);JEV;2(952S;\X=TYRH&%QZ__ ,,T^$?^@O\ $#_PX_B'_P"3J/\ AFGP MC_T%_B!_X=^%_^"?7PS\*>-]/ MUJVU+Q9I?VQIG@B\UIY/#^GWN[<)X;7;D,&+,-SD?,>,<5Z?X+^ /AO MP1#\18+:;4+VW\=ZI;V_P#P3_\ !5K\-?#?A&#QI\0+:X\,W4UQH?B:WUT1:OID MS [5T_B#]CWPGXN^#ME\/\ 7O$GC3738WR:K:>*=3\0 M37&MVUZGW+B*X?(1E!("J@09)VYYKH?^&:?"/_07^('_ (QK2UNEOPM;_ -)7W'._!K]D31O@KKGVW3_B M'\2M>T^&W:VLM!U[Q5//IMC&05 B@0(/E4X7>6V\$88 U5\&_L7^&?"OQ2T[ MQUJ'C7X@^-;W299IM(TWQ=XDEU*RTR21"C/"CC=NV$J"[MZ]0".L_P"&:?"/ M_07^('_AQ_$/_P G4?\ #-/A'_H+_$#_ ,./XA_^3J+OF4KZHEQ3371_U_2V M/5:*\J_X9I\(_P#07^('_AQ_$/\ \G4?\,T^$?\ H+_$#_PX_B'_ .3J0SU6 MBO*O^&:?"/\ T%_B!_X$10JC %>E_\ #-/A'_H+_$#_ ,./XA_^3J%[LE-;H'[T7![,]5HK MRK_AFGPC_P!!?X@?^''\0_\ R=1_PS3X1_Z"_P 0/_#C^(?_ ).H ]5HKRK_ M (9I\(_]!?X@?^''\0__ "=1_P ,T^$?^@O\0/\ PX_B'_Y.H H>%OV=+SP7 MKFJ:CI'Q5\:6R:KJLFKW]H]OHTJW4KL"4DE?3C,R!0L:YDRD:JJD!1BY#^SC MH2A;YJ3_AFGPC_ -!?X@?^''\0_P#R=1_PS3X1_P"@ MO\0/_#C^(?\ Y.I+167E^%O\DWW:3'N[OS_&^GIJ]/-]S%US]E73?$&DP0W' MCCQ8-7_MJ/7[W7#_ &?+<:C=11B.#SX9+-K8I$JQE$2%%5HUDQY@+GTOP1X5 MU/PI8W$&J>,=;\9RRR;TNMN.*X[_AFGPC_P!! M?X@?^''\0_\ R=1_PS3X1_Z"_P 0/_#C^(?_ ).JK]/ZZ+Y:)"WU?];O\VP\ M.?\ )TWQ#_[$SPS_ .EVO5<^-?P;F^+VB_9+/QGK_@V[\B2W,VDR12031OM+ M)-;3H\3\JI#A5D7!"N S!O*- _9[\+R_M)>.M/;5?' MX/"7AZX1U\?:ZLQ: M2\UI6#2B]WNH$2[49BJDN5 +N6]+_P"&:?"/_07^('_AQ_$/_P G4@.N^'/P M^T_X9^&ET?3[B\OB]Q->75_J,HDN;RYF5?\,T M^$?^@O\ $#_PX_B'_P"3J/\ AFGPC_T%_B!_X,_$7A?4/#ZS?8ETF/3YH1)* K3&.[M9U$H0%%D4!E5Y #AVS#JOP-FU MBWT.ZG^(/BM/%FC_ &B.V\60KIT=^8)]OFV\D8L_LKQG9&<- 2#&C @C-1_\ M,T^$?^@O\0/_ X_B'_Y.H_X9I$_P#07^('_AQ_$/\ \G4K:6_K^O\ AMAW MUN;?AOX:#P/IOAG0/#]W)#X8T]+E=0MKUQ<2Z@906+RNZEF=I7>1FWKDLV0V M1MYKPI^S1HGAG5-!DN/$7B+Q#HGASS?^$?\ #NL36\EEI.^-HAY92!9I=D+O M$GVB67:K'OS5K_AFGPC_ -!?X@?^''\0_P#R=1_PS3X1_P"@O\0/_#C^(?\ MY.IO5MOK_7_#=N@NEOZ_KOWZC?#/[.NB^'-0T,2:YK6L^'O#K;_#_AG43:FP MTAA$T*&$I DTFR*22-?/EEP&]0I"^!_V==%\#Z[HU[%KWB#5M-\/I-'X>T/4 MKF)[+15E4HP@V1+))B,F-#/)*40E4*@G*_\ #-/A'_H+_$#_ ,./XA_^3J/^ M&:?"/_07^('_ (H?U_7EY;!^TM_R3K2/^QS$_\ MJ0Z=7JM?+_[0?[/?A?2? >E3P:KXX=V\6^&+E_\,T^$?^@O\0/_ X_B'_Y.I >JT5Y5_PS3X1_Z"_Q _\ M#C^(?_DZC_AFGPC_ -!?X@?^''\0_P#R=0!=^*/@S4KWQ=X%\9Z%9C4-7\.W MLD$UGYBQM/I]TJQ7*JS,JAT*PS#)Y\@KU85TVK>![#6/&WA[Q1-+<+J&B07= MO;QQLHB=;@1ARX*DDCREQ@CJ,/A9;^-;.W^UZYJEMJVGZBVIZ1K5JML M+K2I61H\0;H6C9?+DD3$R29#G=DX(XWQ9\%[NR^&OB3PQH5SJ&MZYXXN/LNO M^*M2>W6Y$,D0AEN9!&L292WC$4:0Q@;C&2H!DD&I_P ,T^$?^@O\0/\ PX_B M'_Y.H_X9I$_]!?X@?\ AQ_$/_R=196MT>_GMI\[*_>RZI#N[WZK;RW_ "OI MV.PU+X?Z7JM_X:GG\XV_A_>UG8!E^S^8T1A61UQEF2-I%7G \QB02%*\W$? M@1HOP>N+N;3=3U;57DL[;2[7^U9(G^P:?;F0V]G#Y<:9CC,TF&DWR'/S.V!B MG_PS3X1_Z"_Q _\ #C^(?_DZC_AFGPC_ -!?X@?^''\0_P#R=57=V^_]?U\^ MY*5H\JV/5:*\J_X9I\(_]!?X@?\ AQ_$/_R=1_PS3X1_Z"_Q _\ #C^(?_DZ MD,]5KRK]FG_DG6K_ /8Y^+/_ %(=1H_X9I\(_P#07^('_AQ_$/\ \G54_93T MV'1?A+=Z?;O<26]IXM\4V\;W=S)WEC'RR%HUE50P)#/ M\N#S73:?^WA;:-WOB3PM:Z-X6FT;0[J]?[/9W-TLL4J%1N$167_ M %NQ[? +X+Z)XZ^%'[+?CN_NM0AU?P3X.M'TZ&VD1;>4W6EP0R>< MI0LV%&5VLN#USTJ]I_["?PLTV3XM(EIJ#Z?\2IH;G5M.:X58+6:)WD62TVH' MB;S)&DY9@& P !MJ5>--Q]7\V]OG'[FO,UDXNWHE_P"3-W^7XI^1\X?"'_@H M7X^^,^E?$7PKI-YX U+QQI_AF?Q!H^O:#;:I#ID0B91+!/%>1+*9E5BZLH,9 M.T'O7TO^P[XH\=^,_P!E[P?KWQ U"QU36-1M?M5O>V;RM)-;,H,;7!D_Y;YW M;MGR?=Q6K\*_V6]+^&.FZ]8W?C[XA^/K?6+1K"2/QGXFFOH[>!EVLD,8"(A( M_CVEQT# $@]#\ _@9IG[//PYM_!6C:]X@U_2;61FMI/$5XMS-;QD "&-E1 L M2X^50,#)]:/DW]UE^J?WZ:'YU?LEZYK'CZ\\! M:CK^N?M9:IJUWJR^=J=A=O-X1?;=$+OE++?PH?[!FU"ZU.SFEGG$GF-&8$MU7RV8G,)/$$/B/QM $\1Q^*K'1UUH-ING:@LXF>2"V:,I^\(VMO#G:<*5X M(VC)<\+_ IZ^EX_I#K#PM\3="N-2TF3P_+=&]MI(+9)F,XE;:%<,"J+G:' +DJ<^]^'_V<_#? MAO1_BAIMM>ZK)!\0[^\U#56FEB+0R7,(BD$&(P%4*,C>'.>I/2H-)_9H\,:/ M>_"2ZAO]6:3X9Z;/I6CB2:(B>*6VCMV:XQ&-S!(U(*;!DG@CBN>*?)9[\L5\ M^67,_P#P+EL.I[S?+IK+[KKE_"]SY:^&_P"U9\5K[X._ .V\$Z)X=O\ Q-\0 M-0UZQD7Q)?ZGV]Q(V93IURNQ()%X"&82 MG)VXUE**FV] M8MK[N>/_ +;S?TE:IKGD^33XOQ]I:_SY/Q"/]JGXTZ3HOQVLM3\!Z#K'C;X> MPZ0MGI?AO[5A?L<_'[Q%\<_#VO2>*= M<\ ZOJVG3QJ8_!+:A"]NCAL+=6M]$DT+94[2!MY\P_96_99\91:'\6+K MX@P^(_AW=>,YM/2WCL/&,E[KL'V6'8;J74X6^>61R6(^[U4H%PM>[? ?]F+P M]\!-0U_5K3Q!XI\9>)-<$,=]X@\8ZJ=0OI(H@WE1"3:H"+N;@#//).!BK_Y]#FNY17*NOX?UM_3/8****S-0HHHH **** "BBB@ HHHH * M*** "BBB@#RK]D[_ )-9^#?_ &)FC?\ I##7JM>5?LG?\FL_!O\ [$S1O_2& M&O5: "BBB@ HHHH *^6+VS\4^$?'VM>//'^C:S;^&5\3I!:7-G\0M35H;=YX MK6S<:/;_ .B/ S&.1Q))OP\A:,X"5]3UY.O[.>CQZM)M\0:XOA-]5_ML^#%^ MR#2_MOGBY\T,+?[3C[2//V>?LWD_+M^6B.E12_K=/[[+1_+9A+6#C_6S7Z[/ MUW5GB_M->--1T6\^'OAFQ@URZA\3ZO-;7EMX:E,&H7,,-G--Y$,XEB^SEY$C M!E\R/:H;YUSFO/H=<_M:X$_#?3-7\?^'H=3\6SVFO:;X@U=I=7TV&/3I+Q; M./4(II)?+F*Q2"5+F5@KR()%V^6GN6N?#&[\96DO]LZ]>V>J66KR:CH.L:6( M!=:4IC,85-$C?*/*I$L<@*R8.XJ&K$;]F[1Y='D$WB3Q%-XK;5DUP>,FFMU MU1;Q(O(1U58!;!1!F'RO(\LH6W(69F*CHFVM[/\ ])=OEK=;7VT)-0L[U;/^SX+O MRY;JWFCFN!']HD4>:[L0(]Q9ANKM?V7/!.K^%/AE%?Z]J.NW.J^()FU=]/US M6;K4VTJ*4 PV:27$LC_NX]@8[CND\QNA &E_PS_H,OPS\0>#+O4]8OXO$5P] MWK.L7%PGVZ_F=D+N[*@C4,L:Q[$145 %55 %>F@!0 !@5:T];13]4M7YW:3N M]?O9+][965V_OV]+)O3;7R1Y7X<_Y.F^(?\ V)GAG_TNUZO5:\J\.?\ )TWQ M#_[$SPS_ .EVO5ZK4C"BBB@ HHHH *\U^,_@W4_%-K8W,=WXCNM&TY99KCPW MX2U Z7J&JS-M6+%Z+JW,:1@R,8_,4.=N6^7:WI5<3X^^%MOXVU33-9L];U3P MGXETV*:VMM4H98"MS#-$R,T43?-&2#&"I'.9DKZ?U_7_#[E1T.; M_9]\1:[K/P)L);^\;6/%6GI=V%REYN$L=U!+)&+>=V +R)M5'E Q(5+J65@Q M^>?A3\6;:SU?X.7>G>/-<\0_$#Q%J;:9X]\.ZEJMQTTG7M/U'6?%OB;QK#I/F_V18>))[>>'3C(C1L MRLD"2SOY3-&)+F29]K-\V68FVWSN7I^%[I=;2O;5/I?;6++D^)O#&M?%'2-8TO4O$>HW%K!<#XA:GJD<5Y,L\XBGTSBR@ MA$<;HAC>4*5BZ$EEU=!^('B3QA^U-X.O8]3N;;P)JWAS6'TK24D M:1:6L+-,8_WS!(@QE01E48,,"20<[J<+*46]E?[G%K5=[]G;YZCEK>V[M]]^ MCWM;OK\M"S^TM_R3K2/^QS\)_P#J0Z=7JM>5?M+?\DZTC_L<_"?_ *D.G5ZK M4@%%%% '*_$;QE+X/T2(:?;I?^(-2F%CI%@[%1<7+ D;B.1&BJTCL.B1N1DX M!\;^!#?$7Q/\!=5L[/QM$_BU/$^MV$OB77+)KTQQ1:A<1[HH!(B[@%4(A;8@ MQ\K!=I]J\;_#7PA\3+*WL_&'A71/%=I;2>;!;ZYIT-Y'$Y&-RK*K!3@D9'.* MQ/@Y\#?"'P'\/ZCHW@_2X=-L[_4+C4IO*MX8B7FD9]G[I$&R,,(T!!*HJKDX MJ;:2OU6GWK_@^I4G[J2[_I)?JC,_9=U/4=9_9]\"WNK:E=:QJ4VFH;B_OI#) M/.^2"[L>I.*\&TWQ-X@C^)#^*;G6?$@L'\?R:\,:-JNHV]AHVQ4D?R7EN(U))CE M)CQM.>2@5N!@CG/&G]F?1&UH.WB/Q$_A5=9_M]?!C3VYTM;[S?/\P'R/M.W[ M1^^\KS_*W_P;?EJX_P 53>WZ7BW]Z37X/W6[Q)?NW!?UHU^=G^*]Y(]?HHHI M#"BBB@ KRK]FG_DG6K_]CGXL_P#4AU&O5:\J_9I_Y)UJ_P#V.?BS_P!2'4: M/-/V9?V>_"^M?LV_"C4+C5?'$=Q=^$M)N)$M/'VNVT*LUG$Q"11WJI&N3PB* M%48 KTO\ X9I\(_\ 07^('_AQ_$/_ ,G5\0?&#Q/K&E_![]C'1[+5OBG: M:3JG@W-_8?".Y=-8N_+TRQ:/;&#M<(Q).X'"ER*/BAKFL>$_V7_"LVCZY^TG MIO\ :WQ(M+&\C\57;Q>+IK=K63?#9!2-T;X!13D&0'(XI1?-'F\TOODH_J6X MVMYIO[DW^A]O_P##-/A'_H+_ ! _\./XA_\ DZC_ (9I\(_]!?X@?^''\0__ M "=7S%^S+:_&M]!^,_\ PCTGQ1CT&;1 /"+?&AX_[:76/*D!*A\@0Y\O&X;, MX_VZB_8'\=:];?%/4?"'C+QE\4(/%4NA"ZO_ =\3[0S;[M)%6:[TV]W#_1Q MNVB'8,A@P9@N1<8\TN7RO^?^7W-/9Z9-VCS>=OR_S^]-;K7ZB_X9I\(_]!?X M@?\ AQ_$/_R=1_PS3X1_Z"_Q _\ #C^(?_DZN*\9^/\ 4]4_;.\,^#8]3N]/ M\.>&/"-WXLU&UM)Y(A?S22_9H4E"D"1(U$CA#QN93R5&/G6[_:4^./Q7MO@G MXWN;#1/"/PQ\6_$+3[?3%T'5;I-6-L))T,%^.(YHY0A;"X V#=9IOF E!:3%R_*E1D+\O7+@N=)KK;\53?_N1?B7.+C+E\[?.\U_[8 MSV3_ (9I\(_]!?X@?^''\0__ "=1_P ,T^$?^@O\0/\ PX_B'_Y.KYNN?V@O MBYX!_:G^-EYXGO-"U'X;>"?"RZR=%LFG2<6QCEDMO)R-OVAV4"5GR ,;.!BN M9_9E_P""FVJ?%3XPZ)X4\3?\(?J%CXB@N9K5/"<6I1W>CO%"TWE7ANXECF+* MI7= JD M:Y/"(H51@ "O2_^&:?"/\ T%_B!_X?$W4/'&@7-U-Y([:-XY$ MAD-Q!&&E9G60OLD!#WJL:?>_X+;U?8)>[3E4[6_%_EY^A]#?\,T^$?\ H+_$ M#_PX_B'_ .3J/^&:?"/_ $%_B!_XJT4 >5?\,T^$?^@O\ $#_P MX_B'_P"3J/\ AFGPC_T%_B!_XJT4 >5?\ #-/A'_H+_$#_ ,./ MXA_^3J/^&:?"/_07^('_ ((_$OQ9U#7X=3>UM M=4N(=+T_0S%9&3S99AO0[\[>]^/5YJ&I>(OAGX,MM3U' M1].\3:W+#J=UI5Q):W#VT%G/<>0D\;+)"7>*,%HV5MH8 C-"UBI+J[?E^"O; MU32O8;M%M/HK_G^=M+VT:O8M_P##-/A'_H+_ ! _\./XA_\ DZC_ (9I\(_] M!?X@?^''\0__ "=7AOB;Q'XBL]/U?X>V>N>)=6@TOXB6^D6]I:ZG.FMZMIC: M?'?O90WX975T+G,TTT9,46UYP7R?9_V9]6O+KPOXCTO4+[4)+G2-=N+5-+UJ M\>\U+2H&6.6*UNKAV8S2!9 PD$DJE74"60+NIQ][5=D_DU%_^W+[GKM=2O!I M/T_]*_\ D7]Z\[>?Z!^SWX7E_:2\=:>VJ^.!;P>$O#UPCKX^UU9BTEYK2L&E M%[O=0(EVHS%5);_MU:?XIF\#0WMG8Z_J_@NRLKZ76=/\+ZC]BOC/L3[-*Q$T+S0*// M#0HQ9G>(['Q\LMV&E<](_P"&:?"/_07^('_AQ_$/_P G4?\ #-/A'_H+_$#_ M ,./XA_^3JU_@;K>BZ[\-["70-=UKQ#I\$UQ:BX\1B1=1@>.9U:VN!*B2^9$ M08_WH,A" NSL2[=]5R7*[$IW1Y5_PS3X1_Z"_P 0/_#C^(?_ ).H_P"&:?"/ M_07^('_AQ_$/_P G5ZK14C/*O^&:?"/_ $%_B!_XI7-MX$U;PYK,FE:2CE8[Q(9K$)?R+T8R&5_+SG; M'M88,C 9?PHL_%/@'Q3X6U?XG:-K.FZKXEU*>SMYD^(6J:HD=Y,L\RQ3Z9Q9 M01"-'1#&\H4B+H266HZ\K?VK_FXI>K:VWZ6N*6E_+_*[?HN^W78G_:#_ &>_ M"^D^ ]*G@U7QP[MXM\,6Y%SX^UV==LFNV$;$+)>L P5R5<#,I?!^B1#3[=+_ ,0: ME,+'2+!V*BXN6!(W$]NG^:_*Z;_ N5 M:R3?5V_!O\;-+I?=H])_X9I\(_\ 07^('_AQ_$/_ ,G4?\,T^$?^@O\ $#_P MX_B'_P"3JSOV8M8U2X\/^*=&UF75(;W1M=G@ATC7[IKS4M,M'1)K>&XNB\@N M&*2;Q(LLH"N$,C,C8Y'XC?$3Q%KWQP^%AT/5;C3_ 3%XLFT6X6V;<1]Z&%XE0#HTHDR/W2$TE>44NMOQM_FEI?7RU(^S*3^S?\+[?7OQ.^%OCCQ3 MJGB#5-3TFRU)-7MDU75M;2[TV4O_21(T(^T1W*),'9&1\NH+!U89# M DC[T5)=KV[:M:]NGWCE[LG'S:OWM;;^NASW_#-/A'_H+_$#_P ./XA_^3J/ M^&:?"/\ T%_B!_XJT4@/*O^&:?"/\ T%_B!_XGV[W$EO:>+?%-O&]W61F>1L#EW8LQR22237L%> M5?LT_P#).M7_ .QS\6?^I#J- 'C/@_\ 9>T?]H3]F_\ 9OU6]\7^,/!>K>&? M!MA]@U#P;J:6%P/M&GVRR R&)VQMC ^4C@MG.:[O0_V.='T_1="T[6/B)\1/ M&G]B^)[7Q79W?BG6TO[A+BW1D2'>T/$!WDE0 2>0PKH-)_93\!Z#I5GIFF7? MCC3M-LH4MK6SM/B%X@BA@B10J1HBWP"JJ@ *!@ "K?_ S3X1_Z"_Q _P## MC^(?_DZB/N?#WO\ .]_SU"7O*S[-?)W3_-G<^./!>C?$;P?K'A?Q#9KJ&B:O M:R6=Y:LS+YD3C##,#XGMO$OC'QCK$.GG2=/E M\7:R;]=+LRRL8+9=BB-#L3U("X!&3GI?^&:?"/\ T%_B!_X>&/$1\V-3;Q;UN+6;:Y!=?,$D;!,M^\4X(!QPVA_\ M$Z?ASX;\6:'K&G>(_'$&G:#KD>OZ/X:?7/-TG39U=G9(;=XSM1V;YB27XX89 M.?4O^&:?"/\ T%_B!_XNI==_NY?RT.7D_8O\ !,GG9U37_P![\0E^)+8N(/\ D)#I$/W/ M_'O_ +/W_P#;KE_B+_P3M^'?Q)\5^*]9N_$OC?2K7Q+>1ZG?Z%I6M"+3&O49 M&^U?9VC8-(=F/G+ ;FP =I'J'_#-/A'_ *"_Q _\./XA_P#DZC_AFGPC_P!! M?X@?^''\0_\ R=2C[KBU]G;[DORC'[D.36\8^T0[-S,%D."' ! (&

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end GRAPHIC 6 regionalsales1.jpg begin 644 regionalsales1.jpg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ⅅ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end GRAPHIC 7 regionalsales2a02.jpg begin 644 regionalsales2a02.jpg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�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end